| NI |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$0.24 vs. cons $0.23 |
MEDIUM |
| NI |
Report |
Q2 2026 Revenue |
IN-LINE |
pred ~$1.25B vs. cons $1.24B |
LOW |
| NI |
Report |
H1 2026 Adjusted EPS (run-rate / % of FY midpoint) |
IN-LINE |
pred ~$1.30 (~64% of $2.045 mid) vs. cons ~$1.29 (~63%) |
MEDIUM |
| NI |
Guide |
FY2026 consolidated adjusted EPS guidance |
UNCHANGED |
guide ~$2.02–2.07 reaffirmed (skew to upper half) vs. cons ~$2.05 (FY2026) |
MEDIUM |
| NI |
Guide |
Long-term consolidated adj. EPS CAGR |
UNCHANGED |
guide 9–10%, tracking high end thru 2030 vs. cons ~9–10% (2026–2033) |
MEDIUM |
| NI |
Guide |
GenCo signed data-center capacity / pipeline |
UNKNOWN |
guide ~4 GW signed, ~9 GW funnel vs. cons hoping for 3 GW-bucket conversion (as of Q2'26) |
MEDIUM |
| NI |
Guide |
GenCo EPS contribution |
UNCHANGED |
guide $0.25–0.35 (2030) / $0.40–0.60 (2033) vs. cons ~$0.30 / ~$0.50 (same) |
LOW |
| NI |
Guide |
FFO/debt target & annual equity funding |
UNCHANGED |
guide 14–16% FFO/debt & $400–600M/yr equity vs. cons ~15% / ~$500M (2026–2033) |
LOW |
| NI |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.5% |
— |
LOW |
| NI |
Return |
5-day cumulative residual |
-1.0% (FADE) |
Seasonally trivial Q2; a modest EPS beat plus a merely-reaffirmed (or upper-half-narrowed) FY guide implies flat-to-lower H2 out-period estimates — the implicit-cut math pulls numbers down even after a beat. Absent a fresh GenCo signing or pipeline/CAGR uplift, elevated data-center expectations aren't re-excited, and NI mean-reverts as it did after the Q1 beat/raise faded ~3%. Any small day-1 relief bounce off 2026 lows gives back over the week. |
LOW |